Men, Don't Skip Your Prostate Cancer Treatment Appointments
Research Finds Missing Two or More Treatment Days Can Lead to a Worse Outcome for Some
LOS ANGELES (Oct. 2007)—Men with "low risk" prostate cancer who miss more than two radiation treatments in an eight week treatment face an increased chance of their cancer recurring. That is the conclusion of a new study examining more than 15 years of data and nearly 1,800 patients treated at Fox Chase Cancer Center in Philadelphia. The results were presented today at the American Society for Therapeutic Radiology and Oncology's 49th Annual Meeting in Los Angeles.
As radiation doses are escalated, overall treatment time has expanded for prostate cancer. A typical course of external beam therapy such as IMRT is about five days a week for eight weeks.
"Eight weeks of treatment is a significant time commitment. As the treatment times continue to increase, the potential for missed treatments increases," said David J. D'Ambrosio, M.D., a resident in the Department of Radiation Oncology at Fox Chase Cancer Center in Philadelphia.
For the study, D'Ambrosio and his colleagues examined the records of 1,796 men treated with external beam radiation between 1989 and 2004. A majority of patients (1,362) received 3D conformal radiation therapy while about a quarter (434) received IMRT, intensity modulated radiation therapy. The men were divided into three groups: low risk, intermediate risk and high risk.
"Our findings show that when men with low risk prostate cancer miss more than two treatment days over eight weeks, their risk of the cancer recurring increases," D'Ambrosio said. "This highlights the importance of finishing treatment without breaks, once it has begun."
Researchers used a ratio for non-treatment days to examine the rate of biochemical failure (recurrence of the cancer based on a rising PSA level). The 10 year rate of biochemical failure in the low risk group was 18 percent when patients had a low non-treatment day ratio versus 43 percent when the patient had a higher non-treatment day ratio (p=0.0019). The significance remained even when the data were analyzed using the absolute number of non-treatment days instead of our non-treatment days ratio, D'Ambrosio said.
"Of the three risk groups, we found a greater pronouncement of biochemical failure among the group at lowest risk. We believe that in the low risk group, controlling cancer in the prostate and keeping it from spreading outside of the prostate makes the greatest difference for these patients. In this study, for men with high and intermediate risk cancers, two days of missed treatment did not seem to have as great an impact. Despite this, treatment breaks are still to be discouraged."
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy6 Moore at 215-728-2700.